495 related articles for article (PubMed ID: 7631404)
1. Platelet refractoriness and alloimmunization in pediatric oncology and bone marrow transplant patients.
Hogge DE; McConnell M; Jacobson C; Sutherland HJ; Benny WB; Massing BG
Transfusion; 1995 Aug; 35(8):645-52. PubMed ID: 7631404
[TBL] [Abstract][Full Text] [Related]
2. Determination
Thuku NW; Shikuku K; Mbugua A
Pan Afr Med J; 2017; 27():226. PubMed ID: 28979628
[TBL] [Abstract][Full Text] [Related]
3. Clinical and laboratory correlates of platelet alloimmunization and refractoriness in the PLADO trial.
Hess JR; Trachtenberg FL; Assmann SF; Triulzi DJ; Kaufman RM; Strauss RG; Granger S; Slichter SJ
Vox Sang; 2016 Oct; 111(3):281-291. PubMed ID: 27185561
[TBL] [Abstract][Full Text] [Related]
4. Human leucocyte antigen alloimmunization after bone marrow transplantation: an association with chronic myelogenous leukaemia.
Geiger TL; Woodard P; Tong X; Srivastava DK; Johnson R; Turner V; Hale G; Richardson S
Br J Haematol; 2002 Jun; 117(3):634-41. PubMed ID: 12028035
[TBL] [Abstract][Full Text] [Related]
5. Posttransfusion purpura following bone marrow transplantation.
Evenson DA; Stroncek DF; Pulkrabek S; Perry EH; Radford J; Miller JS; Verfaillie C
Transfusion; 1995 Aug; 35(8):688-93. PubMed ID: 7631411
[TBL] [Abstract][Full Text] [Related]
6. Bleeding risk and platelet transfusion refractoriness in patients with acute myelogenous leukemia who undergo autologous stem cell transplantation.
Toor AA; Choo SY; Little JA
Bone Marrow Transplant; 2000 Aug; 26(3):315-20. PubMed ID: 10967572
[TBL] [Abstract][Full Text] [Related]
7. [Platelet alloimmunization in patients with oncologic blood disorders treated with multiple transfusions: prospective study in adults and children].
Pereira J; Bronfman L; BertÃn P; Marzouka E; Hidalgo P; Amaya S; Mezzano D
Rev Med Chil; 1997 Nov; 125(11):1305-12. PubMed ID: 9609051
[TBL] [Abstract][Full Text] [Related]
8. Human leukocyte antigen (HLA) class I antibodies and transfusion support in paediatric HLA-matched haematopoietic cell transplant for sickle cell disease.
Nickel RS; Horan JT; Abraham A; Qayed M; Haight A; Ngwube A; Liang H; Luban NLC; Hendrickson JE
Br J Haematol; 2020 Apr; 189(1):162-170. PubMed ID: 31674662
[TBL] [Abstract][Full Text] [Related]
9. Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness.
Seftel MD; Growe GH; Petraszko T; Benny WB; Le A; Lee CY; Spinelli JJ; Sutherland HJ; Tsang P; Hogge DE
Blood; 2004 Jan; 103(1):333-9. PubMed ID: 12958065
[TBL] [Abstract][Full Text] [Related]
10. Human leukocyte antigen (HLA)-incompatible mean fluorescence intensity-selected platelet products have corrected count increments similar to HLA antigen-matched platelets.
Karafin MS; Schumacher C; Zhang J; Simpson P; Johnson ST; Pierce KL
Transfusion; 2021 Aug; 61(8):2307-2316. PubMed ID: 34075590
[TBL] [Abstract][Full Text] [Related]
11. Use of leucocyte-poor blood components and HLA-matched-platelet donors to prevent HLA alloimmunization.
Murphy MF; Metcalfe P; Thomas H; Eve J; Ord J; Lister TA; Waters AH
Br J Haematol; 1986 Mar; 62(3):529-34. PubMed ID: 3954967
[TBL] [Abstract][Full Text] [Related]
12. Analysis of platelet-reactive alloantibodies and evaluation of cross-match-compatible platelets for the management of patients with transfusion refractoriness.
Wang J; Xia W; Deng J; Xu X; Shao Y; Ding H; Chen Y; Liu J; Chen D; Ye X; Santoso S
Transfus Med; 2018 Feb; 28(1):40-46. PubMed ID: 28516675
[TBL] [Abstract][Full Text] [Related]
13. Prevention of refractoriness and HLA-alloimmunization using filtered blood products.
Sniecinski I; O'Donnell MR; Nowicki B; Hill LR
Blood; 1988 May; 71(5):1402-7. PubMed ID: 3282572
[TBL] [Abstract][Full Text] [Related]
14. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions.
Trial to Reduce Alloimmunization to Platelets Study Group
N Engl J Med; 1997 Dec; 337(26):1861-9. PubMed ID: 9417523
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal management with crossmatch-compatible platelets for refractory patients: alloimmunization, response to transfusion, and clinical outcomes (CME).
Wiita AP; Nambiar A
Transfusion; 2012 Oct; 52(10):2146-54. PubMed ID: 23113654
[TBL] [Abstract][Full Text] [Related]
16. Occurrence of allogeneic HLA and non-HLA antibodies after transfusion of prestorage filtered platelets and red blood cells: a prospective study.
Novotny VM; van Doorn R; Witvliet MD; Claas FH; Brand A
Blood; 1995 Apr; 85(7):1736-41. PubMed ID: 7703481
[TBL] [Abstract][Full Text] [Related]
17. Refractoriness to random donor platelet transfusions in patients with aplastic anaemia: a multivariate analysis of data from 264 cases.
Klingemann HG; Self S; Banaji M; Deeg HJ; Doney K; Slichter SJ; Thomas ED; Storb R
Br J Haematol; 1987 May; 66(1):115-21. PubMed ID: 3593647
[TBL] [Abstract][Full Text] [Related]
18. [An evaluation of platelet transfusion response using HLA crossmatch-compatible donors in patients with platelet refractoriness].
Hyun J; Lim YM; Park KD; Han BY; Kim YH; Han KS; Park MH
Korean J Lab Med; 2009 Oct; 29(5):481-9. PubMed ID: 19893359
[TBL] [Abstract][Full Text] [Related]
19. Leukocyte depletion of random single-donor platelet transfusions does not prevent secondary human leukocyte antigen-alloimmunization and refractoriness: a randomized prospective study.
Sintnicolaas K; van Marwijk Kooij M; van Prooijen HC; van Dijk BA; van Putten WL; Claas FH; Novotny VM; Brand A
Blood; 1995 Feb; 85(3):824-8. PubMed ID: 7833483
[TBL] [Abstract][Full Text] [Related]
20. Alloimmunization after leukocyte-depleted multiple random donor platelet transfusions.
Brand A; Claas FH; Voogt PJ; Wasser MN; Eernisse JG
Vox Sang; 1988; 54(3):160-6. PubMed ID: 3369136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]